RS20060273A - Farmaceutske formulacije, metode i protokoli doziranja u lečenju i prevenciji akutnih koronarnih sindroma - Google Patents

Farmaceutske formulacije, metode i protokoli doziranja u lečenju i prevenciji akutnih koronarnih sindroma

Info

Publication number
RS20060273A
RS20060273A YUP-2006/0273A YUP20060273A RS20060273A RS 20060273 A RS20060273 A RS 20060273A YU P20060273 A YUP20060273 A YU P20060273A RS 20060273 A RS20060273 A RS 20060273A
Authority
RS
Serbia
Prior art keywords
methods
acute coronary
prevention
treatment
coronary syndromes
Prior art date
Application number
YUP-2006/0273A
Other languages
English (en)
Inventor
Charles L. Bisgaier
Wendi V. Rodrigueza
Narendra D. Lalwani
Daniel Hartman
Jan Johansson
Original Assignee
Esperion Therapeutics Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc., filed Critical Esperion Therapeutics Inc.,
Publication of RS20060273A publication Critical patent/RS20060273A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Sadašnji pronalazak obezbeđuje metode i formulacije za lečenje i sprečavanje akutnih koronarnih sindroma. Metode trenutnog pronalaska omogućavaju sigurne i delotvorne doze Apolipoprotein A-I Milano: fosfolipidnih kompleksa za redukciju i stabilizaciju arterosklerotičnih naslaga (pločica). Takođe su obezbeđene i farmaceutske formulacije ApoA-I Milano: fosfolipidnih kompleksa.
YUP-2006/0273A 2003-10-20 2004-10-19 Farmaceutske formulacije, metode i protokoli doziranja u lečenju i prevenciji akutnih koronarnih sindroma RS20060273A (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51311603P 2003-10-20 2003-10-20
US51701603P 2003-11-03 2003-11-03
US57112904P 2004-05-14 2004-05-14
PCT/US2004/034800 WO2005041866A2 (en) 2003-10-20 2004-10-19 Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes

Publications (1)

Publication Number Publication Date
RS20060273A true RS20060273A (sr) 2008-09-29

Family

ID=34557347

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2006/0273A RS20060273A (sr) 2003-10-20 2004-10-19 Farmaceutske formulacije, metode i protokoli doziranja u lečenju i prevenciji akutnih koronarnih sindroma

Country Status (24)

Country Link
US (2) US7435717B2 (sr)
EP (1) EP1677597B1 (sr)
JP (1) JP2007509157A (sr)
KR (3) KR20070110561A (sr)
AR (1) AR046126A1 (sr)
AU (2) AU2004284932A1 (sr)
CA (1) CA2542726C (sr)
CO (1) CO5690611A2 (sr)
CR (1) CR8352A (sr)
EA (1) EA010134B1 (sr)
EC (1) ECSP066516A (sr)
ES (1) ES2449719T3 (sr)
GE (1) GEP20094601B (sr)
HK (1) HK1093869A1 (sr)
IL (1) IL174301A (sr)
MA (1) MA28102A1 (sr)
MX (1) MXPA06004362A (sr)
NO (1) NO339456B1 (sr)
NZ (1) NZ545939A (sr)
OA (1) OA13272A (sr)
PA (1) PA8615301A1 (sr)
PE (1) PE20050438A1 (sr)
RS (1) RS20060273A (sr)
WO (1) WO2005041866A2 (sr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8246671B2 (en) 1999-08-09 2012-08-21 Cardiokinetix, Inc. Retrievable cardiac devices
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US8388672B2 (en) 1999-08-09 2013-03-05 Cardiokinetix, Inc. System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
PL372925A1 (en) * 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
CA2486127C (en) * 2002-05-17 2014-03-11 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
US8926958B2 (en) * 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
MX2008001063A (es) * 2005-07-22 2008-03-19 Procter & Gamble Composiciones para reducir la incidencia de arritmia inducida por farmacos.
EP1986735A4 (en) * 2006-02-06 2011-06-29 Northwind Ventures SYSTEMS AND METHODS FOR VOLUME REDUCTION
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
CA2644118A1 (en) * 2006-03-03 2007-09-13 Activbiotics, Inc. Treatment of atherosclerotic disease
DE102007006663A1 (de) * 2007-02-10 2008-08-21 Lts Lohmann Therapie-Systeme Ag Transport von Arzneistoffen über die Blut-Hirn-Schranke mittels Apolipoproteinen
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
MX2011008735A (es) * 2009-02-18 2012-01-12 Cormatrix Cardiovascular Inc Composiciones y metodos para prevenir la arritmia cardiaca.
AU2010217760B2 (en) 2009-02-27 2015-04-09 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US20100234827A1 (en) * 2009-03-13 2010-09-16 Sigg Daniel C Method of treating heart failure
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US8790242B2 (en) * 2009-10-26 2014-07-29 Cardiokinetix, Inc. Ventricular volume reduction
TR201903209T4 (tr) 2010-06-30 2019-03-21 Csl Ltd Yeniden yapılandırılan yüksek yoğunluğa sahip bir lipoprotein formülasyonu ve bunun üretim yöntemi.
BR112013004397A2 (pt) 2010-08-30 2017-06-27 Hoffmann La Roche método para produzir uma partícula de lipídio, a partícula de lipídio em si e seu uso
WO2012028526A2 (en) 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Tetranectin-apolipoprotein a-i, lipid particles containing it and its use
RU2013111676A (ru) 2010-08-30 2014-10-10 Ф. Хоффманн-Ля Рош Аг Способ получения тетранектин-аполипопротеин а-i частицы, полученная таким образом липидная частица и ее применение
PL2767546T3 (pl) 2011-02-07 2019-04-30 Cerenis Therapeutics Holding Sa Kompleksy lipoproteinowe i ich wytwarzanie oraz ich zastosowania
RU2016138742A (ru) * 2011-04-27 2018-12-12 Айсис Фармасьютикалс, Инк. МОДУЛИРОВАНИЕ ЭКСПРЕССИИ АПОЛИПОПРОТЕИНА СIII (АроСIII)
WO2012162392A1 (en) 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
JP6207507B2 (ja) 2011-08-25 2017-10-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 短縮されたテトラネクチン−アポリポプロテインａ−ｉ融合タンパク質、それを含む脂質粒子、及びその使用
EP2793913B1 (en) * 2011-12-21 2023-06-21 CSL Limited Dosage regime for apolipoprotein formulations
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US9125943B2 (en) * 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
WO2014144708A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
EP3062836B1 (en) * 2013-10-31 2018-04-25 Novo Nordisk A/S Injection device with a needle cannula
EP3197397B1 (en) 2014-09-28 2021-01-13 Cardiokinetix, Inc. Apparatuses for treating cardiac dysfunction
WO2016118625A1 (en) * 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
MY187439A (en) * 2015-08-25 2021-09-22 Novo Nordisk As A medical injection device with a cleaning chamber
DE102018107407A1 (de) 2017-03-28 2018-10-04 Edwards Lifesciences Corporation Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US6306433B1 (en) * 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
PL372925A1 (en) 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
CA2486127C (en) * 2002-05-17 2014-03-11 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
IL165253A0 (en) * 2002-05-17 2005-12-18 Esperion Therapeutics Inc Methods and compositions for the treatment of ischemic reperfusion

Also Published As

Publication number Publication date
AU2004284932A1 (en) 2005-05-12
HK1093869A1 (en) 2007-03-16
GEP20094601B (en) 2009-02-10
EA010134B1 (ru) 2008-06-30
CA2542726A1 (en) 2005-05-12
PE20050438A1 (es) 2005-06-14
JP2007509157A (ja) 2007-04-12
ECSP066516A (es) 2006-11-24
CO5690611A2 (es) 2006-10-31
US20050142180A1 (en) 2005-06-30
IL174301A0 (en) 2006-08-01
OA13272A (en) 2007-01-31
MA28102A1 (fr) 2006-08-01
US7435717B2 (en) 2008-10-14
EA200600548A1 (ru) 2006-10-27
NO20062110L (no) 2006-07-18
AU2011202014A1 (en) 2011-05-26
CR8352A (es) 2007-03-02
IL174301A (en) 2013-09-30
EP1677597B1 (en) 2014-01-08
MXPA06004362A (es) 2006-09-04
AR046126A1 (es) 2005-11-23
KR20060080227A (ko) 2006-07-07
WO2005041866A2 (en) 2005-05-12
KR20070110561A (ko) 2007-11-19
KR20100101710A (ko) 2010-09-17
NO339456B1 (no) 2016-12-12
AU2011202014B2 (en) 2012-06-14
EP1677597A2 (en) 2006-07-12
PA8615301A1 (es) 2005-09-28
WO2005041866A3 (en) 2006-05-18
ES2449719T3 (es) 2014-03-20
CA2542726C (en) 2012-05-15
EP1677597A4 (en) 2011-08-24
NZ545939A (en) 2008-08-29
US20080293633A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
RS20060273A (sr) Farmaceutske formulacije, metode i protokoli doziranja u lečenju i prevenciji akutnih koronarnih sindroma
NO20080855L (no) Behandling med azetidinon-baserte kolesterol absorpsjonsinhibitorer og omega-3 fettsyrer og et kombinasjonsprodukt derav
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1111999T1 (el) Λακτοφερρινη στην αγωγη κακοηθων νεοπλασματων και αλλων υπερπλαστικων νοσων
NO20014842D0 (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
IS8395A (is) Fjölvasýklískar karboxýlsýrur og asýlsúlfónamíð sem hindrar á lifrabólgu C eftirmyndun
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
WO2005000211A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
DE60212683D1 (de) Pharmazeutische und kosmetische zusammensetzungen mit oxy-gruppen-tragenden aromatischen aldehyden
HK1068606A1 (en) Novel aminobenzoephenones
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
NO20064753L (no) Kombinasjonsterapi
MXPA02010184A (es) Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia.
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
BR0316010A (pt) Combinação
TNSN06114A1 (fr) Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus
ATE412411T1 (de) Pmcol zur behandlung von prostatakrebs
UY28569A1 (es) Fórmulas farmacéuticas, métodos y regímenes de dosificación para el tratamiento y la prevención de síndromes coronarios agudos
DOP2004001009A (es) Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
GT200500018A (es) Formulas farmaceuticas: metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos.
AU2629500A (en) A method for treating patients with acne by administering a cyclic gmp pde inhibitor